PremiumRatingsOruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target2d agoORKA
Oruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target
PremiumBlurbsAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Omnicell (OMCL) and Guardant Health (GH)2d agoGHNBIX
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Omnicell (OMCL) and Guardant Health (GH)
PremiumBlurbsAnalysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Guardant Health (GH) and Pfizer (PFE)2d agoGHPFE
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Guardant Health (GH) and Pfizer (PFE)